Skip to main content

Table 3 Complications and adverse events

From: Comparison of the efficacy and safety of URSL, RPLU, and MPCNL for treatment of large upper impacted ureteral stones: a randomized controlled trial

Variable URSL group MPCNL group RPUL group P valuea P valueb P valuec
Grade I
 Pain 6/46(13%) 8/50(16%) 9/48(18%) 0.276 0.027 0.795
 Fever 2/46(4.3%) 3/50(6%) 2/48(4.2%) 0.735 0.658 0.743
 Nausea/vomiting 2/46(4.3%) 1/50(2%) 3/48(6%) 0.273 0.342 0.042
 Urine leakage 0/46(0%) 0/50(0%) 3/48(6%) NS <0.001 <0.001
Grade II
 Minor pelvic/ureter perforation 3/46(6.5%) 0/50(0%) 0/48(0%) <0.001 <0.001 NS
 Urinary tract infection 1/46(3%) 1/50(2%) 0/48(0%) NS <0.001 <0.001
 Ureteral stricture 2/46(4.3%) 0/50(0%) 0/48(0%) <0.001 <0.001 NS
Grade III
 Blood transfusion 0/46(0%) 3/50(6%) 0/48(0%) <0.001 NS <0.001
 Grade III - V 0/46(0%) 0/50(0%) 0/48(0%) NS NS NS
  1. aURSL vs. MPCNL; bURSL vs. RPUL; c MPCNL vs. RPUL; NS No Significance